Haleon Pakistan Limited has commenced local manufacturing of Panadol 500mg tablets at its Jamshoro facility, marking a significant milestone in strengthening the company’s domestic production capabilities and supporting the reliable availability of the widely used pain-relief medicine across Pakistan.

In a material information disclosure submitted to the Pakistan Stock Exchange (PSX) on October 30, 2026, Haleon Pakistan Limited announced that it had officially started manufacturing Panadol 500mg tablets at its own manufacturing facility in Jamshoro, Pakistan.

The development follows the company’s previously announced investment, made on October 13, 2023, in its Jamshoro manufacturing facility. The investment was aimed at producing the Panadol base portfolio, introducing modern manufacturing technology to Pakistan, and increasing the company’s overall production capacity.

Strengthening Local Manufacturing Capabilities

The commencement of in-house production represents an important step in Haleon Pakistan’s strategy to strengthen its local manufacturing operations. By shifting Panadol 500mg tablet production to its own facility, the company is enhancing its domestic production capabilities and supporting a more reliable supply of its products to Pakistani consumers.

The investment in the Jamshoro facility was undertaken to bring the latest manufacturing technology to Pakistan while expanding production capacity. The latest development demonstrates progress in implementing that investment.

New Tablet Design Introduced

Alongside the transition to local manufacturing, Panadol 500mg tablets produced at the Jamshoro facility will feature a new tablet design.

Under the updated design, the existing “Panadol” text engraving will be replaced with a beacon engraving. However, Haleon Pakistan has clarified that the change is limited to the tablet’s appearance, while the product’s quality and efficacy will remain unchanged.

This means consumers will notice a difference in the tablet’s engraving, but the company has confirmed that its established quality and effectiveness will be maintained.

Positive Development for Pakistan’s Pharmaceutical Sector

The start of local manufacturing is a significant milestone for Haleon Pakistan and reflects the company’s continued investment in strengthening its manufacturing infrastructure.

Expanding domestic production capabilities can support the availability of essential consumer healthcare products while contributing to the development of Pakistan’s local manufacturing sector.

For Haleon Pakistan, the development represents progress toward building stronger in-house production capabilities and improving the reliability of its product supply chain.

Conclusion

Haleon Pakistan’s commencement of Panadol 500mg tablet manufacturing at its Jamshoro facility marks an important development for the company and the country’s consumer healthcare industry. Supported by its earlier investment in modern manufacturing technology and expanded production capacity, the initiative is expected to strengthen local production capabilities and support the reliable availability of Panadol products in Pakistan.

The company has also confirmed that the newly introduced tablet engraving is purely a design change, with quality and efficacy remaining unchanged.